Affiliation:
1. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Abstract
Abstract
Circulating biomarkers have emerged as valuable surrogates for evaluating disease states in solid malignancies. Their relative ease of access and rapid turnover has bolstered clinical applications in monitoring treatment efficacy and cancer progression. In this review, the roles of various circulating biomarkers in monitoring treatment response are described. Non-specific markers of disease burden, tumor markers (eg CA 125, CEA, PSA, etc.), circulating tumor cells, nucleic acids, exosomes, and metabolomic arrays are highlighted. Specifically, the discovery of each of these markers is reviewed, with examples illustrating their use in influencing treatment decisions, and barriers to their application noted where these exist. Finally, opportunities for future work using these circulating biomarkers are discussed.
Publisher
Oxford University Press (OUP)
Reference150 articles.
1. Apoptotic markers in cancer;Holdenrieder;Clin Biochem,2004
2. Circulating cell death products predict clinical outcome of colorectal cancer patients;Koelink;BMC Cancer,2009
3. The usefulness of lactate dehydrogenase measurements in current oncological practice;Forkasiewicz;Cell Mol Biol Lett,2020
4. Effect of irradiation and operation on serum lactic dehydrogenase and glutamic oxalacetic transminase in patients with malignant tumors;Hoch-Ligeti;Cancer,1962
5. Serum lactic dehydrogenase activity after excision of transplanted tumors;Hsieh;Cancer Res,1959
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献